Empowering People with Parkinson’s disease

Our digital health platform connects People living with Parkinson's Disease to their Interdisciplinary Care Team
for a better quality life at a lower cost

Parkinson's disease

Parkinson’s disease is the fastest growing neurodegenerative disorder. It is a complex chronic neurodegenerative disease that is highly individualized. Numerous symptoms occur in unique combinations, and disease progression and timing is unique for each individual

Motor symptoms

Motor symptoms that affect movement include:
Tremor – a shaking of the hands, arms, or legs.
Rigidity – abnormal stiffness in a part of the body
Postural instability – impaired balance or difficulty standing or walking
Bradykinesia – gradual loss and slowing down of spontaneous movement

Non-motor symptoms

People with Parkinson’s are often more impacted by their non-motor symptoms than motor symptoms.  Examples of non-motor symptoms include fatigue, depression, apathy, difficulty swallowing or chewing, urinary problems, constipation, loss of smell, sleep problems, pain, and cognitive problems.

Quality of Life

Quality of Life (QoL) is a multi-dimensional construct, which consists of at least three broad domains: physical, mental and social.
QoL specifically focuses on the impact of an illness and/or treatment on patients’ perception of their status of health and on subjective well-being or satisfaction with life.

Globally, neurological disorders are the leading cause of disability.

Of these, Parkinson’s disease is the fastest growing and a global concern that is present in every region of the world. Although there is no cure, treatment options vary and include medication, physical activity, life-style changes and surgery.

An estimated 10 million people are diagnosed with Parkinson’s disease worldwide, and this does not consider the millions that are already living with Parkinson’s without being diagnosed. Recent forecasts estimate a doubling of patients in the next generation.

The annual cost of Parkinson’s disease in the United States alone is estimated at $52 billion for 1 million people living with the disease.

51 disease-modifying therapies and 48 symptomatic therapies are in clinical testing, the global pharma market for Parkinson’s is estimated to grow to $6 billion by 2022.

A 2013 study supported by the American Academy of Neurology (AAN) showed an 11% shortage in neurologists at that time and projected a 19% shortage by 2025.

Our Partners

Our recent blogs

European Headquarters

La Lanterne, Rue Jean Burgers 2, 7850 Enghien
Technologielaan 9, 3001 Heverlee
Email: contact@neuropath.life

North American Operations

United States:
NeuroPath US, Inc.
222 W. Merchandise Mart Plaza, suite 1230
Chicago, IL 60654
Email: contact@neuropath.life